Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma

Published:2022-07-11 Issue:4 Volume:19 Page:693-701
ISSN:1612-9059
Container-title:Esophagus
language:en
Short-container-title:Esophagus

Author:

Guo Jhe-Cyuan^ORCID,Lin Chia-Chi,Hsu Chia-Lang,Huang Ta-Chen,Kuo Hung-Yang,Lin Chen-Yuan,Lien Ming-Yu,Cheng Ann-Lii,Hsu Chih-Hung^ORCID

Funder

Ministry of Science and Technology, Taiwan

Ministry of Health and Welfare

National Taiwan University Hospital

National Taiwan University Cancer Center

National Health Research Institutes

National Taiwan University

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

https://link.springer.com/content/pdf/10.1007/s10388-022-00940-7.pdf

Reference28 articles.

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

2. Guo JC, Huang TC, Lin CC, et al. Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma. J Thorac Oncol. 2015;10:1481–9.

3. The Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541:169–75.

4. Kuo HY, Guo JC, Hsu CH. Anti-PD-1 immunotherapy in advanced esophageal squamous cell carcinoma: A long-awaited breakthrough finally arrives. J Formos Med Assoc. 2020;119:565–8.

5. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506–17.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3